Skip to Content

Comvax (haemophilus b conjugate (prp-omp) vaccine / hepatitis b pediatric vaccine) Disease Interactions

There are 2 disease interactions with Comvax (haemophilus b conjugate (prp-omp) vaccine / hepatitis b pediatric vaccine):

Moderate

Hepatitis B Vaccine (Includes Comvax) ↔ Hemophilia

Moderate Potential Hazard, Moderate plausibility

Applies to: Bleeding Associated with Coagulation Defect

Hepatitis B vaccine (adult and pediatric) is usually for intramuscular administration. However, it may be administered subcutaneously to persons at risk for hemorrhage following intramuscular injections (e.g., hemophiliacs), although it may result in lower antibody response. Additionally, when other aluminum- absorbed vaccines have been administered subcutaneously, an increased incidence of local reactions including subcutaneous nodules has been observed. Therefore, consider subcutaneous administration only in persons who are at risk of hemorrhage following intramuscular injections.

Moderate

Hepatitis B Vaccine (Includes Comvax) ↔ Low Birth Weight

Moderate Potential Hazard, Moderate plausibility

Applies to: Prematurity/Underweight in Infancy

Hepatitis B vaccine should be deferred for infants with a birth weight less than 2,000 grams if the mother is documented to be HBsAg negative at the time of the infant's birth. If the mother is HBsAg positive (or the status cannot be determined), the infant should receive the vaccine within 12 hours after birth.
Apnea following intramuscular vaccination has been observed in some infants born prematurely and the decision to administer any intramuscular vaccine, including hepatitis B vaccine, should be based on consideration of the infant's medical status, and the potential benefits and risks of vaccination. Close monitoring is recommended.

Comvax (haemophilus b conjugate (prp-omp) vaccine / hepatitis b pediatric vaccine) drug Interactions

There are 171 drug interactions with Comvax (haemophilus b conjugate (prp-omp) vaccine / hepatitis b pediatric vaccine)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide